OncoMatch/Clinical Trials/NCT05526924
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Is NCT05526924 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Pamiparib and Hydroxyurea for head and neck cancer.
Treatment: Pamiparib · Hydroxyurea · Fluorouracil (5FU) · Tislelizumab — The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and neck cancer, which means that the person's cancer has come back after treatment. Participation in the study should last for about 15 months while participants receive tislelizumab and chemoradiotherapy with pamiparib. Afterwards, they will return to the clinic for follow up every 4 months for 2 years, every 6 month for the next 2 years, and then once a year for the rest of their life.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: HPV p16 immunohistochemistry (IHC) positivity (p16 positive)
Human papillomavirus (HPV) testing for oropharynx primary tumors by p16 immunohistochemistry (IHC) positivity
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radiation therapy
previously irradiated head and neck squamous cell carcinoma
Cannot have received: chemotherapy
Exception: permitted if completed ≥ 1 month before study entry and recovered from adverse effects
Patients who have had chemotherapy within 4 weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
Lab requirements
Blood counts
Patients must have normal organ and marrow functions as defined by lab values that will be confirmed by the study doctor.
Kidney function
Patients must have normal organ and marrow functions as defined by lab values that will be confirmed by the study doctor.
Liver function
Patients must have normal organ and marrow functions as defined by lab values that will be confirmed by the study doctor.
Patients must have normal organ and marrow functions as defined by lab values that will be confirmed by the study doctor.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Chicago · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify